We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

113 hedge funds and large institutions have $468M invested in Relmada Therapeutics in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 50 increasing their positions, 24 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 24

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

16% more call options, than puts

Call options by funds: $29.1M | Put options by funds: $25.2M

3.72% more ownership

Funds ownership: 78.58% → 82.3% (+3.7%)

0% more funds holding

Funds holding: 113 → 113 (0)

25% less capital invested

Capital invested by funds: $623M → $468M (-$155M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
113
Holders Change
–
Holders Change %
0%
% of All Funds
1.9%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
16
Increased
50
Reduced
24
Closed
13
Calls
$29.1M
Puts
$25.2M
Net Calls
+$3.9M
Net Calls Change
-$9.11M

Top Buyers

1
TCM
Tang Capital Management
California
+$8.72M
2
DTC
Deep Track Capital
Connecticut
+$8.68M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$5.2M
4
BlackRock
BlackRock
New York
+$4.36M
5
SFM
Sphera Funds Management
Israel
+$3.83M

Top Sellers

1
MP
Mangrove Partners
Connecticut
-$6.97M
2
ACM
Altium Capital Management
New York
-$3.88M
3
MB
MPM BioImpact
Massachusetts
-$3.73M
4
Millennium Management
Millennium Management
New York
-$3.51M
5
CAC
Cowen and Company
New York
-$2.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
26
Dimensional Fund Advisors
Texas
$3.83M +$1.76M +80,860 +67%
Goldman Sachs
27
Goldman Sachs
New York
$3.5M +$3.38M +154,883 +529%
T. Rowe Price Associates
28
T. Rowe Price Associates
Maryland
$3.21M +$244K +11,192 +7%
ABG
29
Ally Bridge Group
New York
$3.04M +$3.49M +160,000 New
CS
30
Candriam SCA
Luxembourg
$2.7M +$142K +6,510 +5%
PA
31
Perceptive Advisors
New York
$2.3M -$654K -30,000 -20%
Millennium Management
32
Millennium Management
New York
$2.25M -$3.51M -161,079 -58%
Walleye Capital
33
Walleye Capital
New York
$2.02M -$367K -16,809 -14%
N
34
Nuveen
North Carolina
$1.65M +$344K +15,782 +22%
AllianceBernstein
35
AllianceBernstein
Tennessee
$1.46M +$1.29M +59,132 +330%
Charles Schwab
36
Charles Schwab
California
$1.38M +$120K +5,510 +8%
Citigroup
37
Citigroup
New York
$1.19M +$606K +27,796 +80%
Norges Bank
38
Norges Bank
Norway
$1.08M +$1.24M +56,700 New
Parallax Volatility Advisers
39
Parallax Volatility Advisers
California
$1.05M +$1.2M +55,081 New
Swiss National Bank
40
Swiss National Bank
Switzerland
$887K -$205K -9,400 -17%
CSS
41
Cubist Systematic Strategies
Connecticut
$785K +$165K +7,586 +22%
BG
42
Bellevue Group
Switzerland
$665K +$414K +19,000 +119%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$635K +$259K +11,876 +55%
AW
44
Apricus Wealth
South Carolina
$633K -$13.1K -600 -2%
MHC
45
Meyer Handelman Company
New York
$618K – – –
Manulife (Manufacturers Life Insurance)
46
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$590K +$360K +16,499 +116%
WMSA
47
Weiss Multi-Strategy Advisers
New York
$570K +$491K +22,500 +300%
HS
48
HighVista Strategies
Massachusetts
$560K +$177K +8,112 +38%
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$541K -$59.2K -2,715 -9%
ACM
50
Altium Capital Management
New York
$532K -$3.88M -178,000 -86%
1
2
3 4 5

RLMD Hedge Fund Activity: Q2 2022 in Review

113 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q2 2022, worth a combined $468M — down 25% from $623M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new RLMD positions and 13 closed out — a net gain of 3 holders — while 50 added to existing stakes and 24 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $8.72M. The largest seller was Mangrove Partners, exiting entirely with an estimated $6.97M sold.

  • 113 institutional investors held Relmada Therapeutics (RLMD) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $468M of Relmada Therapeutics stock for Q2 2022, down 25% quarter-over-quarter.
  • 16 funds opened new Relmada Therapeutics positions in Q2 2022 and 13 closed out, a net change of +3 holders.
  • The largest Relmada Therapeutics buyer in Q2 2022 was Tang Capital Management, an estimated $8.72M added.
  • The largest Relmada Therapeutics seller in Q2 2022 was Mangrove Partners, an estimated $6.97M sold.

Based on aggregated 13F filings for Q2 2022.